SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Malawi " 12 found 🔀 AI-powered Shuffle
Global Health & WASH
The US National Institutes of Health reopened its center and program-project machinery in force. NIGMS is funding Collaborative Program Grants for interdisciplinary teams, NIAID opened both its Immune Tolerance Network and a next-generation R&D call, the NCI runs its Carcinogen Hazard Assessment Monographs program, the National Library of Medicine is funding institutional training in biomedical AI and data science, and NIH reopened its Centers for AIDS Research. The tell: these pay for standing centers and multi-year consortia at institutions with an existing funded research base, not one-off projects, so the fit is an established US research institution, not a single investigator. Disease-specific foundations are again funding the researcher, not just the research. The Parkinson’s Foundation opened its Paul Oreffice Innovations in Care Award and the National Ataxia Foundation its Research Seed Money Grant. The tell, the same one we flagged last cycle, is a named early-career or seed award that builds a pipeline of scientists committed to one condition, so what wins is a researcher willing to specialize. The post-USAID global-health money is routing through a State Department program statement and multilateral innovation funds. The US Department of State’s Bureau of Global Health Security and Diplomacy opened its Advancing Global Health Annual Program Statement, Grand Challenges Canada opened Nexa Lighthouse for climate and health innovation in Asia and the Pacific at USD $250,000 to $2,000,000, and CEPI opened a rolling call on vaccine-manufacturing analytics. The tell: the largest health money this cycle sits in a standing program statement and in staged innovation vehicles, not in a single bilateral grant. Total Estimated Funding Pool: ~$35.4M across discrete grants. (Separately, large national-formula envelopes not counted in this total: U.S. Department of State, Bureau of Global Health Security and Diplomacy (GHSD).) This post is for paid subscribers. This helps support the time and effort it takes to curate and organize these opportunities. Subscribe To keep this accessible to everyone who needs it, we’re happy to offer pay what you can rates. You can find more details here. New opportunities: Paul Oreffice Innovations in Care Award, Parkinson’s Foundation. *New!* *Closing soon!* The Parkinson’s Foundation created the Paul Oreffice Innovations in Care Award to fund clinicians rethinking how people with Parkinson’s disease receive care. The Foundation is using pilot funding to move promising ideas into testable projects, backing work across four lanes: strengthening community clinician capability, redesigning care models, building patient-centered technologies, and defining the minimum clinical datasets that make better standards possible. It wants hypothesis-driven, clinically grounded projects that can generate evidence strong enough to attract further funding. By opening the door to clinicians at every career stage and strongly preferring projects that involve people with Parkinson’s in their design, the Foundation signals that it values practical, patient-shaped innovation over prestige. The strongest fits are US-licensed clinicians with a focus on Parkinson’s and an institutional home for applied care research. Geographies: united states. Who can apply: Clinicians of all career stages, from fellows to established faculty, who are licensed to care for patients in the United States and have a significant focus on Parkinson’s disease. Physicians must have completed a neurology residency (or justify how their training pathway benefits people with PD); allied health professionals must hold an advanced degree, typically a PhD. Fellows, those in mentored positions, and those within two years of starting an independent position require a mentor and a mentor support letter. The sponsoring institution’s grants office is the authorized recipient and funds are disbursed to the institution. Funding amount: Maximum of $200,000 over two years; up to three awards. Targeted Sectors / SDGs: Health; Innovation; Science & Technology. Deadline: November 1, 2026. Learn more and apply here. Design and Deliver the Next EIT Health Bootcamps, EIT Health. *New!* *Closing soon!* EIT Health is opening its call for consortia to design and deliver the next generation of its health start-up bootcamps, funding the curriculum, masterclasses, mentoring, and investor engagement that turn early health ventures into fundable companies. The organization is using these learning paths to strengthen Europe’s health innovation pipeline across digital health evidence, deep tech and AI commercialization, cross-border investment, and patient access. What EIT Health wants to back is not a single course but durable delivery capacity built by partners who span industry, education, and research. Requiring multi-country consortia and a revenue-sharing stake in the programs signals that EIT Health expects these bootcamps to outlast the grant. The strongest fits are established training providers, universities, and industry partners with proven reach into health entrepreneurs. Geographies: Europe. Who can apply: Consortia only (individuals cannot apply), comprising a minimum of two and a maximum of five independent legal entities. Partners must cover at least two sides of the Knowledge Triangle (industry, education, research), including at least one industry organisation, and at least two entities must be legally established in different Horizon Europe countries. Funding amount: Foundational Learning Path: up to EUR €112,000; Thematic Learning Paths: up to EUR €124,500 per path (up to four thematic projects); up to EUR €610,000 total EIT Health funding available under the call. Targeted Sectors / SDGs: Health; Innovation; Science & Technology; Economic Development & Livelihoods. Deadline: November 2, 2026. Learn more and apply here. Technology Transfer Offices & Entrepreneurship Support Call (Beyond the Lab: From Research to Venture), EIT Health. *New!* *Closing soon!* EIT Health is opening its Technology Transfer Offices and Entrepreneurship Support Call to fund consortia that will deliver the Beyond the Lab: From Research to Venture program for healthcare researchers. EIT Health is using the grant to build local capacity for turning laboratory science into incorporated start-ups, paying experienced technology transfer offices and entrepreneurship support providers to run masterclasses, structured mentoring, and a closing Pitch Day across two cohorts. It wants to back organizations that can walk researchers from discovery to company formation, not just teach theory. Requiring two transfer offices plus one venture-building provider signals that EIT Health values proven commercialization experience alongside academic reach. The strongest fits are European research-commercialization teams with a track record of moving health innovations toward investable ventures. Geographies: Europe. Who can apply: A consortium of two Technology Transfer Offices (representing higher education institutions or research organisations) and one Entrepreneurship Support Provider with demonstrated experience in venture building and start-up support. Applicants may apply for more than one learning path where they can demonstrate the required expertise and capacity for each. Funding amount: Up to EUR €77,000 in 2027 and up to EUR €77,000 in 2028 (up to EUR €154,000 total per consortium over two years). Targeted Sectors / SDGs: Health; Innovation; Science & Technology; Economic Development & Livelihoods. Deadline: November 2, 2026. Learn more and apply here. EIT Health RIS Country Representatives Call (2027-2028), EIT Health. *New!* *Closing soon!* EIT Health is seeking organizations to serve as Country Representatives across eleven Regional Innovation Scheme countries in central and eastern Europe for the 2027 to 2028 period. The money funds a national anchor in each country, an organization that maps the local health innovation ecosystem, connects startups and researchers to EIT Health programs, and builds the stakeholder relationships that let health ventures grow. EIT Health is backing local capacity rather than individual projects, which is why it accepts both single organizations and national consortia that span education, research, and industry. The requirement for co-financing signals that it wants representatives already embedded in their national systems. The strongest fits are established ecosystem builders with deep ties to health innovation stakeholders in one eligible country. Geographies: Croatia; Czech Republic; Estonia; Greece; Hungary; Latvia; Malta; Romania; Serbia; Slovenia; Turkey. Who can apply: Registered legal entities established in one of the eligible EIT RIS countries. Single organisations or national consortia may apply. Consortia must include at least two sides of the Knowledge Triangle (education, research and industry), and all consortium partners must be established in the same eligible country. Suitable applicants have demonstrated experience in healthcare innovation ecosystem development, innovation support and entrepreneurship, start-up acceleration, technology transfer, research and higher education, business support, and stakeholder engagement, with strong links to national innovation stakeholders. Funding amount: Up to EUR €182,000 per Country Representative (maximum funding per project); total call budget up to EUR €1,274,500; EIT Health funds up to 60% of total eligible project costs. Targeted Sectors / SDGs: Health; Innovation; Science & Technology; Economic Development & Livelihoods. Deadline: November 2, 2026. Learn more and apply here. Architects of Trust: Community-Driven Demand Creation for New TB Vaccines, Treatment Action Group (TAG). *New!* *Closing soon!* Treatment Action Group, with funding from Wellcome, is opening its Architects of Trust call to help communities prepare for the new tuberculosis vaccines now moving through late-stage trials. The money backs civil society and community-based organizations to raise awareness, surface local questions and concerns, and press policymakers toward equitable national rollout. By pairing each grantee with an advocacy mentor and running a strategy workshop alongside the Global TB Vaccine Forum, Treatment Action Group is building a durable advocacy bench rather than funding one-off outreach. The two-stage design, starting with a short expression of interest, signals that fit and community rootedness matter more than polished proposals. The strongest fits are locally trusted groups with real TB, immunization, or health advocacy experience and a committed project lead. Geographies: Brazil; Ethiopia; India; Indonesia; Kenya; Malawi; Mozambique; Nigeria; Peru; Philippines; South Africa; Tanzania; Vietnam; Zambia. Who can apply: National, subnational, or regional civil society organizations (CSOs) or community-based organizations based in one of the 14 eligible countries or in Eastern Europe/Central Asia regional networks, with experience in TB, immunization, or other health advocacy and in community engagement or policy advocacy; well integrated into stakeholder networks with membership or affiliation to other CSO or community networks; naming a dedicated project lead (’architect of trust’) who can attend the April 2027 Zaragoza forum in person; and holding (or committing to adopt) organizational policies on safeguarding (bullying, harassment, abuse, and harm), equity, diversity and inclusion, and legal compliance, research practice and governance. Funding amount: Grants of up to US$45,000 will be awarded to 8 CSO partners across 14 high-TB-burden countries plus regional networks in Eastern Europe and Central Asia; each grant funds 12 months of work. Targeted Sectors / SDGs: Health; Governance; Policy & Advocacy. Deadline: November 4, 2026. Learn more and apply here.
Shaping the Future of Global Health: 'Go Healthy with Taiwan 2026' Unveils Top 20 Innovators from 62 Nations
TAIPEI, Taiwan, October 02, 2026--The "Go Healthy with Taiwan 2026" global proposal campaign has selected 20 semifinalists from 832 proposals across 62 countries, with two more rounds of selection still to come. The 20 shortlisted teams hail from 16 countries worldwide, including Australia, Brazil, Canada, Ethiopia, France, India, Israel, Japan, Malawi, New Zealand, Philippines, Poland, Spain, Tunisia, Ukraine, and U.S.A., fully demonstrating strong international diversity and innovative energy.
How Energy Justice Is Changing Women’s Lives in Blantyre
By Temwanani Banda, Blantyre, Malawi Every day, before I think about my business, my family or even myself, there is one question that has always come first: How will we cook today? For many women in Blantyre District, Malawi, cooking begins long before a pot is placed on the fire. It begins with finding fuel. […]
Why Don't Insects Live in the Ocean? Scientists Just Ruled Out One Possible Explanation Thanks to Deep-Diving Fly Larvae
Researchers thought that insects might not live there because their respiratory systems would implode from water pressure. But certain fly larvae in East Africa make daily trips toward the bottom of Lake Malawi with the help of strong air sacs that contain a stretchy protein
These insect submariners survive depths that should crush them
Lake fly larvae plunge more than 200 meters into Lake Malawi each day to hide from predators, using tiny air sacs to control their depth. A rubber-like material called resilin lets them expand or shrink the sacs by changing their pH. Their toughness challenges a popular explanation for why insects are absent from the open ocean.
Colonialism and the role of science in the history of Lake Malawi's fisheries
Many scholars have studied the effects of colonial management on terrestrial resources, but what about the effect of colonialism on bodies of water? A new article in Isis: A Journal of the History of ...
Australia becomes the 30th country to eliminate trachoma as a public health problem
The World Health Organization (WHO) has validated Australia for eliminating trachoma as a public health problem, marking a significant milestone in the health of indigenous peoples and in global efforts to combat neglected tropical diseases (NTDs). Trachoma, the world’s leading infectious cause of blindness, no longer represents a public health problem in the country.Australia is among a growing number of countries that have successfully eliminated trachoma, contributing to global progress towards the targets set out in the WHO road map for NTDs 2021–2030.Trachoma is caused by the bacterium Chlamydia trachomatis and spreads through close contact with infected individuals, contaminated surfaces, and flies that carry eye and nose discharge. Repeated infections can lead to scarring of the eyelids, turning eyelashes inward, and ultimately causing blindness if untreated.“WHO congratulates Australia on this important achievement,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This success reflects sustained commitment, strong partnerships, and a focus on reaching populations most affected by health inequities. It brings us closer to a world free from the suffering caused by trachoma.”Australia’s journey to eliminationAustralia’s achievement reflects decades of targeted public health action, particularly in remote Aboriginal and Torres Strait Islander communities, where trachoma persisted despite its earlier disappearance from the rest of the country.National efforts intensified with the establishment of the National Trachoma Management Programme in 2006, which implemented the WHO-recommended SAFE strategy: surgery for trichiasis, antibiotics to treat infection, promotion of facial cleanliness, and environmental improvement. Regular screening of all communities classified as at-risk of trachoma by teams of qualified health workers formed an important part of the Programme. Interventions were delivered through coordinated partnerships between federal and state governments, Aboriginal community-controlled health services, and local communities.Over time, sustained screening, treatment, and prevention activities, including improvements in housing, water, sanitation and hygiene, led to a steady decline in trachoma prevalence. Australia’s approach included adaptations to reflect its context, such as targeted treatment based on community-level data rather than mass drug administration, and strong integration with environmental health programmes.“Elimination of trachoma is a win for the eye health of communities across Australia, particularly those whose lives have been impacted by a disease that is entirely preventable,” said Mark Butler, Minister for Health and Ageing, Australia. “This major milestone is thanks to Aboriginal and Torres Strait Islander leadership, community commitment and sustained investment over many decades.“The lessons from this work will inform how we approach other preventable health conditions in remote and regional Australia. Aboriginal Community Controlled Health Organisations and local health workers have been central to this success, delivering culturally safe care and community-led solutions.”“This recognition from the World Health Organization reflects decades of work led by Aboriginal Community Controlled Health Organisations, alongside local health workers in remote First Nations communities,” said Malarndirri McCarthy, Minister for Indigenous Australians. “Their work has been critical to eliminating trachoma as a public health problem in Australia.”Advancing global efforts against neglected tropical diseases (NTDs)Trachoma is one of 21 diseases and disease groups that are regarded by WHO as NTDs. Together, NTDs affect more than 1 billion people worldwide, primarily in underserved populations with limited access to essential services such as clean water, sanitation, and health care.Australia’s elimination of trachoma as a public health problem highlights the importance of sustained political commitment and cross-sectoral collaboration in addressing the underlying determinants of health. It also underscores the feasibility of eliminating trachoma even in geographically challenging settings.In addition to trachoma, Australia has several endemic NTDs, including Buruli ulcer, leprosy and scabies. Validation of elimination of trachoma as a public health problem marks the first time that WHO has confirmed the elimination of an NTD in Australia, which becomes the 63rd country globally and 16th in the Western Pacific Region to have eliminated at least one NTD.“Tackling neglected tropical diseases in the Western Pacific Region has long been a challenge for countries across the socioeconomic spectrum, given the complexities in reaching the most vulnerable communities, including in remote areas,” said Dr Saia Ma’u Piukala, WHO Regional Director for the Western Pacific. “As a doctor from Tonga, I’ve experienced these challenges for myself. But I also know that with strategic commitment underpinned by optimal resources and partnerships in health, success is possible as other countries in our region have also demonstrated. I commend Australia on eliminating trachoma as a public health problem and urge all involved to remain vigilant to ensure this status is maintained.”WHO continues to support countries working to eliminate trachoma and other NTDs, ensuring that progress reaches those most in need and that gains are sustained through strong surveillance, appropriately integrated into national health systems, and mainstreamed within the wider health sector and beyond.Editor’s notesNeglected tropical diseases and trachoma elimination effortsNeglected tropical diseases are associated with devastating health, social and economic consequences. Their burden is mainly felt among impoverished communities in tropical areas.Public health targets for the control, elimination and eradication of these conditions were set in the road map for neglected tropical diseases 2021–2030 (https://www.who.int/publications/i/item/9789240010352).In 1996, WHO launched the WHO Alliance for the Global Elimination of Trachoma by 2020 (GET2020), creating a network of governments, non-governmental organizations and academic institutions dedicated to the fight against trachoma. WHO continues to support endemic countries to accelerate progress towards the global target of eliminating trachoma as a public health problem worldwide; 2030 is the new target date.Elimination of trachoma as a public health problem is defined as: (i) a prevalence of trachomatous trichiasis (TT) “unknown to the health system” of < 0.2% in ≥15-year-olds; and (ii) a prevalence of trachomatous inflammation—follicular (TF) in children aged 1–9 years of < 5%, in each formerly endemic district, plus (iii) the existence of a system to identify and manage incident cases of TT.Other countries validated by WHO as having eliminated trachoma as a public health problem are: Algeria, Benin, Burundi, Cambodia, China, Egypt, Fiji, Gambia, Ghana, India, Iraq, Islamic Republic of Iran, Lao People’s Democratic Republic, Libya, Malawi, Mali, Mauritania, Mexico, Morocco, Myanmar, Nepal, Oman, Pakistan, Papua New Guinea, Saudi Arabia, Senegal, Togo, Vanuatu and Viet Nam.
U.S. Forging a Healthier Oceania Through Trump Administration's America First Global Health Strategy Through Bilateral Health Memorandum of Understanding with Papua New Guinea - U.S. Embassy & Consulates in China
United States Forging a Healthier Oceania Through Trump Administration’s America First Global Health Strategy Through Bilateral Health Memorandum of Understanding with Papua New Guinea Press Statement Thomas “Tommy” Pigott, Principal Deputy Spokesperson April 23, 2026 Yesterday the United States and Papua New Guinea signed a five-year bilateral Memorandum of Understanding (MOU) through the Trump Administration’s America First Global Health Strategy. The landmark health MOU focuses on effectively addressing emerging infectious diseases and ongoing outbreaks, building and maintaining surge-response capacities, and enabling Papua New Guinea’s government to independently manage new health threats before they spread internationally. Working with Congress, the United States intends to provide $15 million through December 2030 through the jointly decided health MOU, building on decades of progress in reducing HIV infections and transmissions in Papua New Guinea. The government of Papua New Guinea intends to allocate up to $3 million to disease control programs and strengthen health systems at the national and provincial levels. Up to $5 million under the health MOU will directly support global health security funding, advancing our shared commitment to health security in the region. Through the signing of this $18 million MOU, we are bolstering infectious disease prevention and response by leveraging cost-effective, nationally-driven approaches, with the goal of increasing Papua New Guinea’s health system self-sufficiency. America First Global Health Strategy Memoranda of Understanding (MOUs) signed so far represent more than $20.6 billion in new health funding, including more than $12.8 billion in U.S. assistance alongside $7.8 billion in co-investment from recipient countries, building on decades of progress fighting HIV/AIDS, malaria, tuberculosis, and other infectious diseases around the world. As of April 22, the State Department has signed 32 bilateral global health MOUs with Angola, Bolivia, Botswana, Burkina Faso, Burundi, Cambodia, Cameroon, Côte d’Ivoire, the Democratic Republic of the Congo, the Dominican Republic, El Salvador, Eswatini, Ethiopia, Guatemala, Guinea, Honduras, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mozambique, Niger, Nigeria, Panama, Papua New Guinea, the Philippines, Rwanda, Senegal, Sierra Leone, Tajikistan, and Uganda.
EL PAÍS: US aid cuts collapse Malawi’s LGBTQ+ health services as volunteers scramble to fill the void
The lack of funding has left some 15,000 users of NGO programs scrambling for care in a public system that many fear to enter.
US aid cuts collapse Malawi’s LGBTQ+ health services as volunteers scramble to fill the void
The lack of funding has left some 15,000 users of NGO programs scrambling for care in a public system that many fear to enter
Scientists just found DNA “supergenes” that speed up evolution
Hidden within fish DNA are powerful genetic twists that may explain one of nature’s biggest mysteries: how new species form so quickly. In Lake Malawi, hundreds of cichlid fish species evolved at lightning speed, and scientists now think “flipped” sections of DNA—called chromosomal inversions—are the secret. These inversions lock together useful gene combinations, creating “supergenes” that help fish rapidly adapt to different environments, from deep waters to sandy shores.
Driving Progress on the America First Global Health Strategy Through Bilateral Global Health MOU with Malawi - United States Department of State
Under the America First Global Health Strategy, the United States is advancing a new model of global health assistance—one that prioritizes the protection of the American people from infectious disease threats while empowering recipient countries to achieve self-reliance and accountability within their national healthcare systems. Today, the United States and the Government of Malawi signed a five-year, $936 million bilateral health cooperation Memorandum […]